Ser172
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser172  -  CBX1 (human)

Site Information
EERLTWHsyPsEDDD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 6208902

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 )
Disease tissue studied:
breast cancer ( 4 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 4 )
Relevant cell line - cell type - tissue:
breast ( 2 , 4 ) , HeLa (cervical) ( 1 , 3 , 9 , 10 ) , Jurkat (T lymphocyte) ( 8 )

Upstream Regulation
Treatments:
ionizing_radiation ( 1 ) , vorinostat ( 1 )

References 

1

Legartová S, et al. (2019) DNA Damage Changes Distribution Pattern and Levels of HP1 Protein Isoforms in the Nucleolus and Increases Phosphorylation of HP1β-Ser88. Cells 8
31533340   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

4

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

5

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

6

Rikova K (2012) CST Curation Set: 13916; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -;
Curated Info

7

Rikova K (2011) CST Curation Set: 13128; Year: 2011; Biosample/Treatment: cell line, MGH-6/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

8

Guo A (2011) CST Curation Set: 11985; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

9

Zhou J (2010) CST Curation Set: 9275; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

10

Zhou J (2010) CST Curation Set: 9270; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info